Bavarian Nordic (OTCMKTS:BVNRY) Sees Strong Trading Volume – What’s Next?
by Scott Moore · The Cerbat GemShares of Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 21,280 shares were traded during mid-day trading, an increase of 730% from the previous session’s volume of 2,564 shares.The stock last traded at $9.9496 and had previously closed at $9.9360.
Bavarian Nordic Price Performance
The firm has a market capitalization of $2.42 billion, a P/E ratio of 11.57 and a beta of 1.27. The stock’s 50-day simple moving average is $9.93 and its two-hundred day simple moving average is $10.42.
Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($0.20) earnings per share for the quarter. The firm had revenue of $226.16 million during the quarter. Bavarian Nordic had a return on equity of 11.44% and a net margin of 22.20%. On average, analysts forecast that Bavarian Nordic will post 0.67 earnings per share for the current fiscal year.
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.
The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.